Cargando…

Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator

BACKGROUND: P2RX7 is a purinergic receptor with pleiotropic activities that is activated by high levels of extracellular ATP that are found in inflamed tissues. P2RX7 has immunomodulatory and anti-tumor proprieties and is therefore a therapeutic target for various diseases. Several compounds are dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Janho dit Hreich, Serena, Juhel, Thierry, Hofman, Paul, Vouret-Craviari, Valérie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811721/
https://www.ncbi.nlm.nih.gov/pubmed/36600200
http://dx.doi.org/10.1186/s12575-022-00188-6
_version_ 1784863585537622016
author Janho dit Hreich, Serena
Juhel, Thierry
Hofman, Paul
Vouret-Craviari, Valérie
author_facet Janho dit Hreich, Serena
Juhel, Thierry
Hofman, Paul
Vouret-Craviari, Valérie
author_sort Janho dit Hreich, Serena
collection PubMed
description BACKGROUND: P2RX7 is a purinergic receptor with pleiotropic activities that is activated by high levels of extracellular ATP that are found in inflamed tissues. P2RX7 has immunomodulatory and anti-tumor proprieties and is therefore a therapeutic target for various diseases. Several compounds are developed to either inhibit or enhance its activation. However, studying their effect on P2RX7’s activities is limited to in vitro and ex vivo studies that require the use of unphysiological media that could affect its activation. Up to now, the only way to assess the activity of P2RX7 modulators on the receptor in vivo was in an indirect manner. RESULTS: We successfully developed a protocol allowing the detection of P2RX7 activation in vivo in lungs of mice, by taking advantage of its unique macropore formation ability. The protocol is based on intranasal delivery of TO-PRO™-3, a non-permeant DNA intercalating dye, and fluorescence measurement by flow cytometry. We show that ATP enhances TO-PRO™-3 fluorescence mainly in lung immune cells of mice in a P2RX7-dependant manner. CONCLUSIONS: The described approach has allowed the successful analysis of P2RX7 activity directly in the lungs of WT and transgenic C57BL6 mice. The provided detailed guidelines and recommendations will support the use of this protocol to study the potency of pharmacologic or biologic compounds targeting P2RX7. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12575-022-00188-6.
format Online
Article
Text
id pubmed-9811721
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98117212023-01-05 Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator Janho dit Hreich, Serena Juhel, Thierry Hofman, Paul Vouret-Craviari, Valérie Biol Proced Online Methodology BACKGROUND: P2RX7 is a purinergic receptor with pleiotropic activities that is activated by high levels of extracellular ATP that are found in inflamed tissues. P2RX7 has immunomodulatory and anti-tumor proprieties and is therefore a therapeutic target for various diseases. Several compounds are developed to either inhibit or enhance its activation. However, studying their effect on P2RX7’s activities is limited to in vitro and ex vivo studies that require the use of unphysiological media that could affect its activation. Up to now, the only way to assess the activity of P2RX7 modulators on the receptor in vivo was in an indirect manner. RESULTS: We successfully developed a protocol allowing the detection of P2RX7 activation in vivo in lungs of mice, by taking advantage of its unique macropore formation ability. The protocol is based on intranasal delivery of TO-PRO™-3, a non-permeant DNA intercalating dye, and fluorescence measurement by flow cytometry. We show that ATP enhances TO-PRO™-3 fluorescence mainly in lung immune cells of mice in a P2RX7-dependant manner. CONCLUSIONS: The described approach has allowed the successful analysis of P2RX7 activity directly in the lungs of WT and transgenic C57BL6 mice. The provided detailed guidelines and recommendations will support the use of this protocol to study the potency of pharmacologic or biologic compounds targeting P2RX7. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12575-022-00188-6. BioMed Central 2023-01-04 /pmc/articles/PMC9811721/ /pubmed/36600200 http://dx.doi.org/10.1186/s12575-022-00188-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Methodology
Janho dit Hreich, Serena
Juhel, Thierry
Hofman, Paul
Vouret-Craviari, Valérie
Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
title Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
title_full Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
title_fullStr Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
title_full_unstemmed Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
title_short Protocol for Evaluating In Vivo the Activation of the P2RX7 Immunomodulator
title_sort protocol for evaluating in vivo the activation of the p2rx7 immunomodulator
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811721/
https://www.ncbi.nlm.nih.gov/pubmed/36600200
http://dx.doi.org/10.1186/s12575-022-00188-6
work_keys_str_mv AT janhodithreichserena protocolforevaluatinginvivotheactivationofthep2rx7immunomodulator
AT juhelthierry protocolforevaluatinginvivotheactivationofthep2rx7immunomodulator
AT hofmanpaul protocolforevaluatinginvivotheactivationofthep2rx7immunomodulator
AT vouretcraviarivalerie protocolforevaluatinginvivotheactivationofthep2rx7immunomodulator